|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.
With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
Read
our publications on the go in the Samedan app for iPhone and iPad. You
can download issues for offline reading and our archives go as far back
as 2008! Download for free on the App Store. 
|
|
|
|
|
|
Widgets Magazine
Widgets Magazine
Widgets Magazine
 |
Industry Events |
 |
SMi’s 9th Annual Biosimilars & Biobetters Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Following the success of our previous events in both London and the US,
Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker
line-up and bring together a global audience of biosimilar experts to
discuss the latest developments and future of the rapidly evolving and
expanding biosimilars market.
More info >> |
|
 |
News and Press Releases |
 |
Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for pharmaceutical and medical device applications
Novo Nordisk Pharmatech A/S has entered into an agreement with Signet
Chemical Corporation Pvt. Ltd. for the distribution of their
pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to
the healthcare industry in India, Bangladesh and Sri Lanka.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: 2nd Quarter 2014
Synergy Research Group
The Ministry of Health of Russian Federation approved 194 new clinical
trials of all types including local and bioequivalence studies during
the 2nd Quarter of 2014 (3% less than at the same period of the last
year).
The main contribution to the total number of studies was
made by multinational multi-center clinical trials (MMCT) and the number
of these studies stayed the same as in Q2 2013 – 81 studies. The number
of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to
59 in Q2 2014, a 22% decrease from last year’s figure. The number of
local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical
trials in Q2 2014.
More info >> |
|
|
